Overview
Invests in companies involved in psychedelic medicine research and development. Highly speculative, early-stage sector with significant regulatory risk.
Top Holdings
| Ticker | Holding | Weight |
|---|---|---|
| CMPS | Compass Pathways | 12.4% |
| ATAI | ATAI Life Sciences | 10.8% |
| MNMD | MindMed Inc. | 9.8% |
| NUMI | Numinus Wellness | 8.4% |
| CYBN | Cybin Inc. | 7.8% |
| FTRP | Field Trip Health | 5.8% |
| AWKS | Awakn Life Sci. | 5.4% |
| BCLI | Bright Minds Bio | 4.8% |
| MMED | Mind Medicine | 4.4% |
| HAVN | Havn Life Sciences | 3.8% |
Fund Details
Investment Thesis
Psychedelic-assisted therapy is generating compelling clinical trial results in psychiatry. COMPASS Pathways psilocybin therapy has received FDA Breakthrough Therapy designation for treatment-resistant depression. With mental health disorders representing a massive unmet medical need, successful regulatory approval of psychedelic medicines could unlock a multi-billion dollar therapeutic market.
Who It's For
Highly speculative investors with a very high risk tolerance and a long-term thesis on psychedelic medicine becoming an FDA-approved therapeutic category. This is early-stage biotech investing with significant binary risk around clinical trials and regulatory decisions. Suitable only as a very small position within a diversified portfolio for investors who fully understand clinical and regulatory stage risk.
10-Year History
| Year | Close | % Chg |
|---|---|---|
| 2016 | -- | -- |
| 2017 | -- | -- |
| 2018 | -- | -- |
| 2019 | -- | -- |
| 2020 | -- | -- |
| 2021 | -- | -- |
| 2022 | $8.42 | -- |
| 2023 | $6.82 | -19.0% |
| 2024 | $5.18 | -24.0% |
| 2025 | $5.84 | +12.7% |
| Year | Yield |
|---|---|
| 2016 | -- |
| 2017 | -- |
| 2018 | -- |
| 2019 | -- |
| 2020 | -- |
| 2021 | -- |
| 2022 | 0.00% |
| 2023 | 0.00% |
| 2024 | 0.00% |
| 2025 | 0.00% |
| Year | AUM | % Chg |
|---|---|---|
| 2016 | -- | -- |
| 2017 | -- | -- |
| 2018 | -- | -- |
| 2019 | -- | -- |
| 2020 | -- | -- |
| 2021 | -- | -- |
| 2022 | $0.04B | -- |
| 2023 | $0.04B | +0.0% |
| 2024 | $0.04B | +0.0% |
| 2025 | $0.04B | +0.0% |
Historical figures are ETFHub estimates modelled from asset-class return patterns and may differ from official fund records. Data as of August 2026.
Related US Sectors ETFs
Markets. Intelligence. Daily.
Full briefs on 251 ETFs, curated daily ETF news, and a free weekly deep-dive newsletter — all on ETFHub.
Get the Free Weekly Brief Explore the ETF Portal Official Fund Page →